Cidara's Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment
None The FDA approved Cidara Therapeutics Inc's (NASDAQ: CDTX) antifungal Rezzayo (rezafungin) under priority review for treating candidemia and invasive…
Source: biztoc.com